Published in Br Med J (Clin Res Ed) on September 25, 1982
Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology (1997) 1.36
Large hepatocellular cancers: hepatic resection or liver transplantation? Br Med J (Clin Res Ed) (1985) 1.19
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res (2013) 1.13
Fibrolamellar carcinoma: 2012 update. Scientifica (Cairo) (2012) 1.06
The changing face of hepatic resection. Curr Probl Surg (1989) 0.96
Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Gastrointest Cancer Res (2014) 0.91
Focal liver lesions: a plan for management. Br Med J (Clin Res Ed) (1985) 0.91
The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients. Oncotarget (2015) 0.86
Cobalamin and folate binding proteins in human tumour tissue. J Clin Pathol (1984) 0.85
Fibrolamellar carcinoma of the liver. Review of three cases and the presentation of a characteristic set of tumor markers defining this tumor. Ann Surg (1985) 0.84
Genomic homogeneity in fibrolamellar carcinomas. Gut (2001) 0.80
A young woman with liver cancer. Gastrointest Cancer Res (2013) 0.76
Fibrolamellar hepatocellular carcinoma complicating ulcerative colitis with primary sclerosing cholangitis. Gut (1989) 0.76
Urinary dopa metabolites. Br Med J (Clin Res Ed) (1984) 0.75
Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J Hepatocell Carcinoma (2015) 0.75
Distribution of vitamin B12 R-binder in carcinomas of the digestive tract. J Clin Pathol (1988) 0.75
Advances in neoplastic disease of the liver and biliary tract. Gut (1991) 0.75
RAPID CHARCOAL ASSAY FOR INTRINSIC FACTOR (IF), GASTRIC JUICE UNSATURATED B12 BINDING CAPACITY, ANTIBODY TO IF, AND SERUM UNSATURATED B12 BINDING CAPACITY. Blood (1965) 5.83
Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer (1980) 3.82
Serum vitamin B12 and transcobalamin abnormalities in patients with cancer. Cancer (1977) 1.29
Isolation and characterization of a novel vitamin B12-binding protein associated with hepatocellular carcinoma. J Clin Invest (1975) 1.15
A tumor-related vitamin B12 binding protein in adolescent hepatoma. N Engl J Med (1973) 1.12
A rare case of megaloblastic anaemia caused by disturbances in the plasma cobalamin binding proteins in a patient with hepatocellular carcinoma. Scand J Haematol (1975) 1.02
Characterization of a cobalamin-binding plasma protein from a patient with hepatoma. Scand J Clin Lab Invest (1975) 0.96
Vitamin B12 binding protein as a tumour marker for hepatocellular carcinoma. Gut (1978) 0.94
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet (1998) 6.88
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet (1999) 3.54
Do housemen take an adequate drinking history? Br Med J (1980) 3.44
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol (2002) 3.11
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy (2007) 2.88
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res (1999) 2.87
Overexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells. Mol Cell Biol (1985) 2.87
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med (1992) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Liver in Felty's syndrome. Br Med J (1970) 2.75
Liver disease among homosexual males. Lancet (1979) 2.74
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
The anatomy and transcription of a telomeric expression site for variant-specific surface antigens in T. brucei. Cell (1987) 2.63
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol (2000) 2.58
Liver transplantation. Curr Probl Surg (1979) 2.57
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
The systemic inflammatory response syndrome in acute liver failure. Hepatology (2000) 2.47
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Attentional bias in anxiety and depression: the role of awareness. Br J Clin Psychol (1995) 2.43
Bowel preparation at home: prospective study of adverse effects in elderly people. BMJ (1996) 2.43
Developing and deploying a patient safety program in a large health care delivery system: you can't fix what you don't know about. Jt Comm J Qual Improv (2001) 2.42
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 2.41
1 -Antitrypsin deficiency and neonatal hepatitis. Br Med J (1972) 2.40
General practice orthopaedic outpatient referrals in North Staffordshire. Br Med J (Clin Res Ed) (1983) 2.38
Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr (1993) 2.32
Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol (1992) 2.31
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet (1982) 2.30
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs. Lancet (1970) 2.25
Cytomegalovirus hepatitis in the adult. Lancet (1967) 2.20
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res (1999) 2.19
Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ (1990) 2.18
Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain. Lancet (1973) 2.17
Assessment of non-mydriatic fundus photography in detection of diabetic retinopathy. Br Med J (Clin Res Ed) (1986) 2.16
Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care (1999) 2.16
Portal hypertension in idiopathic tropical splenomegaly. Lancet (1966) 2.16
Choriocarcinoma and partial hydatidiform moles. Lancet (2000) 2.15
Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet (1968) 2.14